Silvia Ling

513 total citations
16 papers, 298 citations indexed

About

Silvia Ling is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Silvia Ling has authored 16 papers receiving a total of 298 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 10 papers in Molecular Biology and 6 papers in Oncology. Recurrent topics in Silvia Ling's work include Multiple Myeloma Research and Treatments (10 papers), Ubiquitin and proteasome pathways (5 papers) and Protein Degradation and Inhibitors (5 papers). Silvia Ling is often cited by papers focused on Multiple Myeloma Research and Treatments (10 papers), Ubiquitin and proteasome pathways (5 papers) and Protein Degradation and Inhibitors (5 papers). Silvia Ling collaborates with scholars based in Australia, United States and Canada. Silvia Ling's co-authors include Tara L. Roberts, James M. Lee, Harry Iland, P. Joy Ho, Shaun Fleming, John Allen, D. Joshua, Noemi Horvath, Simon J. Harrison and Alberto Catalano and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Clinical Pathology.

In The Last Decade

Silvia Ling

14 papers receiving 295 citations

Peers

Silvia Ling
Manuela Gambella Italy
Valentina Agnusdei Italy
Colin A. Martz United States
Valerie Morris United States
Paola Rivera-Muñoz France
Y-T Tai United States
Esther Tijchon Netherlands
Trine Kristiansen Sweden
Caroline Alvares United Kingdom
Liliana H. Mochmann Germany
Manuela Gambella Italy
Silvia Ling
Citations per year, relative to Silvia Ling Silvia Ling (= 1×) peers Manuela Gambella

Countries citing papers authored by Silvia Ling

Since Specialization
Citations

This map shows the geographic impact of Silvia Ling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Silvia Ling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Silvia Ling more than expected).

Fields of papers citing papers by Silvia Ling

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Silvia Ling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Silvia Ling. The network helps show where Silvia Ling may publish in the future.

Co-authorship network of co-authors of Silvia Ling

This figure shows the co-authorship network connecting the top 25 collaborators of Silvia Ling. A scholar is included among the top collaborators of Silvia Ling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Silvia Ling. Silvia Ling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
2.
Bryant, Christian, Dipti Talaulikar, Adam Bryant, et al.. (2024). A single‐day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies. European Journal Of Haematology. 113(4). 521–529.
3.
Kalff, Anna, Peter Mollee, P. Joy Ho, et al.. (2023). The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma Australia. Internal Medicine Journal. 53(5). 819–824. 6 indexed citations
4.
Ma, Yafeng, et al.. (2023). The use of cell free DNA (cfDNA) for mutational screening of multiple myeloma. Leukemia Research Reports. 20. 100393–100393. 2 indexed citations
5.
Talaulikar, Dipti, Douglas Joshua, John Gibson, et al.. (2022). Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal. 53(4). 599–609. 1 indexed citations
6.
Pothula, Srinivasa, Xin Maggie Wang, Tiffany Khong, et al.. (2021). The Role of Chaperone-Mediated Autophagy in Bortezomib Resistant Multiple Myeloma. Cells. 10(12). 3464–3464. 14 indexed citations
7.
Ling, Silvia, et al.. (2021). Resistance to Targeted Therapies in Multiple Myeloma. 1 indexed citations
8.
9.
Ling, Silvia, et al.. (2020). Comparing the area under the curve and peak height methods in the calculation of FLT3‐ITD allelic ratio. International Journal of Laboratory Hematology. 42(5). e234–e236. 1 indexed citations
10.
Lee, James M., et al.. (2018). Endoplasmic reticulum stress in the development of multiple myeloma and drug resistance. Clinical & Translational Immunology. 7(1). e1007–e1007. 73 indexed citations
11.
Ling, Silvia, et al.. (2015). Molecular mechanisms in multiple myeloma drug resistance. Journal of Clinical Pathology. 69(2). 97–101. 54 indexed citations
12.
13.
Ling, Silvia, Alberto Catalano, Harry Iland, et al.. (2011). Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. Haematologica. 97(1). 64–72. 103 indexed citations
14.
Ling, Silvia, et al.. (2008). Characterization of Bortezomib Resistance in Multiple Myeloma Cell Lines. Blood. 112(11). 2639–2639. 2 indexed citations
15.
Ling, Silvia, Douglas Joshua, John Gibson, et al.. (2006). Transformation and progression of Waldenström's macroglobulinemia following cladribine therapy in two cases: natural evolution or iatrogenic causation?. American Journal of Hematology. 81(2). 110–114. 11 indexed citations
16.
Ling, Silvia, et al.. (2004). Attention increases perceived saturation. Journal of Vision. 4(8). 329–329. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Manuela Gambella Breakdown of academic impact, for papers by Valentina Agnusdei Breakdown of academic impact, for papers by Colin A. Martz Breakdown of academic impact, for papers by Valerie Morris Breakdown of academic impact, for papers by Paola Rivera-Muñoz Breakdown of academic impact, for papers by Y-T Tai Breakdown of academic impact, for papers by Esther Tijchon Breakdown of academic impact, for papers by Trine Kristiansen Breakdown of academic impact, for papers by Caroline Alvares Breakdown of academic impact, for papers by Liliana H. Mochmann
Rankless by CCL
2026